Deloitte’s 14th annual report on pharma innovation reveals a modest uptick in R&D returns for 2023, with the projected internal rate of return (IRR) for the pharma sector rising to 4.1% after hitting a low of 1.2% in 2022. Yet the report emphasizes the need for biopharma companies to adapt to ongoing challenges and leverage…
Two-thirds of pharma companies plan to up IT investments in 2024, survey finds
Two out of three pharma companies (67%) plan to ramp up investment in IT, including AI, over the next 12 months, according to a survey from the cloud vendor Rackspace Technology and Dell/VMware conducted in October 2023. About the same amount, 68%, reported challenges in recruiting and hiring talent skilled in cloud and AI technology.…
The evolution of drug discovery: Opportunities and obstacles with ML and AI development
The potential for artificial intelligence (AI) and machine learning (ML) to reshape drug discovery and development is immense. From expediting learning and driving discoveries to managing large-scale data sets and generating fresh insights, the true scale of AI’s influence on the industry is only starting to be understood. But with great potential comes great responsibility.…
Data-driven insights into the leading causes of death, including cardiovascular disease and cancer
Data sourced from Our World in Data Cardiovascular disease and cancer remain the leading causes of death in the world, based on an analysis of data sources ranging from World Health Organization and Our World in Data. While respiratory illnesses were the third most common cause of death in 2019, deaths in this category…
New AI tool InClinico predicts clinical trial outcomes with 79% accuracy: A closer look with InSilico CEO, Alex Zhavoronkov
Roughly nine out of ten clinical trials fail as a result of factors such as lack of efficacy and unmanageable toxicity, as the journal Pharma Excipients has noted. After seven years of development, Insilico Medicine has scored a breakthrough with its generative AI tool, inClinico. In particular, the tool demonstrated 79% accuracy in predicting the…
The big spenders: The top 25 pharma companies in R&D investments
In the throes of the COVID-19 pandemic, when the world was desperate for a lifeline, the global pharma sector’s R&D prowess was thrust into the limelight. Now, as the pandemic begins to loosen its grip, the sector continues to make aggressive investments in research and development (R&D). At the tip of the spear of this…
Pharma R&D investment returns sink to 13-year low
A recent Deloitte report revealed that the declining trend in pharma R&D returns, evident before the pandemic, continued in 2022. The return on investment in R&D has generally declined since 2010. The latest Deloitte report on pharma innovation showed a steady fall in the internal rate of return (IRR) on R&D from 2014 to 2017, with a…
Pharma R&D ROI hits highest level since 2014
The pharmaceutical industry appears to have addressed a decade-long decline in R&D productivity, according to a recent analysis from Deloitte. In 2021, the projected R&D return on investment (ROI) rose 7%. For comparison, the ROI level in 2010 was 2.7%. Forecast peak sales per asset hit $521 million, up more than 23% over the $422 million…